Dilated Cardiomyopathy

• Myocardial injury and initial contractile dysfunction: The inciting event varies by etiology but fundamentally results in loss or dysfunction of cardiomyocytes. In genetic forms (sarcomeric proteins like β-myosin heavy chain, cardiac troponins, or titin mutations), there is direct impairment of the force-generating apparatus. In inflammatory cardiomyopathy (myocarditis), infectious agents or autoimmune mechanisms cause myocyte necrosis and inflammation. Toxic insults (alcohol, chemotherapy agents like anthracyclines, cocaine) induce oxidative stress and mitochondrial dysfunction, leading to apoptosis. In peripartum cardiomyopathy, hormonal changes and oxidative stress from prolactin cleavage products contribute to myocyte injury. This initial loss of contractile function reduces the ventricle's ability to generate force and eject blood efficiently.

• Neurohormonal activation and maladaptive compensation: As cardiac output falls, multiple compensatory mechanisms activate acutely to maintain systemic perfusion but become chronically deleterious. The sympathetic nervous system increases norepinephrine release, enhancing contractility and causing vasoconstriction; chronic β-adrenergic overstimulation leads to β₁-receptor downregulation and desensitization, progressive myocardial dysfunction, apoptosis, and arrhythmias. The renin-angiotensin-aldosterone system (RAAS) is activated by reduced renal perfusion and baroreceptor sensing; angiotensin II increases afterload through vasoconstriction, promotes aldosterone secretion (increasing sodium and water retention and causing hypokalemia), stimulates myofibroblast proliferation, and directly causes cardiomyocyte apoptosis and fibrosis. Elevated natriuretic peptides (BNP, NT-proBNP) attempt to counterbalance with vasodilation and natriuresis but are insufficient in advanced disease. Elevated catecholamines and angiotensin II also promote inflammatory cytokine production (TNF-α, IL-6), further impairing contractility.

• Ventricular remodeling and structural maladaptation: Progressive myocardial fibrosis develops through activation of cardiac fibroblasts by TGF-β, angiotensin II, and inflammatory cytokines; collagen deposition in the interstitium reduces ventricular compliance and impairs contractile function. Eccentric hypertrophy develops as the ventricle dilates to accommodate increased wall stress via the Frank-Starling mechanism; while initial dilation maintains stroke volume, progressive dilation moves the ventricle onto a flatter portion of the Frank-Starling curve where further stretch fails to increase contractility. Myocardial sarcomere disarray and loss of organized myofibril architecture occur with certain genetic mutations and in response to chronic stretch. Changes in chamber geometry alter the orientation of contractile fibers, reducing the mechanical efficiency of contraction. The dilated, spherical ventricle generates greater wall tension for any given contractile force (elevated Laplace stress), further impairing function in a vicious cycle.

• Calcium handling abnormalities and excitation-contraction coupling dysfunction: In many forms of DCM, there is impaired sarcoplasmic reticulum calcium release and reuptake. Phospholamban, a regulatory protein that inhibits the sarcoplasmic/endoplasmic reticulum calcium-ATPase (SERCA2a), becomes hyperphosphorylated under chronic sympathetic stimulation, further reducing calcium reuptake and diastolic relaxation. Mutations in SERCA2a, ryanodine receptor (RyR2), or phospholamban itself impair calcium cycling. Elevated diastolic calcium and abnormal calcium handling promote arrhythmias and cell death. Calcineurin-mediated dephosphorylation of phospholamban is enhanced in chronic heart failure, perpetuating impaired relaxation.

• Mitochondrial dysfunction and energetic collapse: Cardiomyocytes require enormous ATP production (the heart consumes ~6 kg of ATP daily); mitochondrial dysfunction limits ATP generation. In toxic DCM (alcohol, chemotherapy), direct mitochondrial injury occurs. Chronic sympathetic overstimulation increases oxygen consumption while mitochondrial efficiency decreases. ROS generation from oxidative stress and uncoupling of oxidative phosphorylation lead to further myocyte apoptosis. This energetic deficit contributes to irreversible contractile dysfunction.

• Alterations in myocardial gene expression: Chronic pathological stress induces fetal gene expression patterns (α-MHC to β-MHC shift, upregulation of natriuretic peptides, skeletal actin isoforms), which are less efficient for contraction. Growth factors (FGF, IGF-1) and stress kinases (p38 MAPK, ERK1/2) promote maladaptive hypertrophy rather than compensatory adaptation.

• Electrical remodeling and arrhythmia substrate: Prolonged action potential duration, abnormal calcium handling, and scar formation create substrate for reentrant arrhythmias. Downregulated potassium channels (Kv4.3, Kv1.5) and upregulated late inward current prolong repolarization. These changes underlie the high incidence of atrial fibrillation and sudden cardiac death in DCM.

• Idiopathic/Genetic cardiomyopathy (~50% of cases): This represents the largest category in developed nations when no secondary cause is identified. Sarcomeric protein mutations account for 20-30% of familial cases and include β-myosin heavy chain (MYH7), cardiac troponins (TNNT2, TNNI3), α-tropomyosin (TPM1), and regulatory light chains; these mutations impair force generation or calcium sensitivity. Titin (TTN) mutations, the most common monogenic cause of DCM, account for ~10% of familial cases through haploinsufficiency; titin provides elasticity and supports the Z-disk. Cytoskeletal protein mutations (dystrophin in X-linked DCM, desmoplakin, desmin, and α-actinin) impair mechanical coupling. Z-disk protein mutations (LIM domain proteins, muscle-specific ring finger proteins) disrupt protein-protein interactions. Mitochondrial DNA mutations cause energy depletion. Genetic testing is increasingly recommended, particularly in early-onset cases, familial disease, or unexplained DCM. Male sex, family history, and early presentation (age <50 years) suggest genetic etiology.

• Myocarditis and inflammatory cardiomyopathy: Viral myocarditis (particularly enterovirus, parvovirus B19, human herpesvirus 6, and increasingly COVID-19) causes acute myocyte necrosis and inflammation; while some patients recover, others progress to chronic DCM with persistent viral persistence or autoimmune sequelae. Fulminant myocarditis presents with acute cardiogenic shock and may recover with aggressive support. Autoimmune myocarditis occurs with systemic lupus erythematosus, sarcoidosis, giant cell myocarditis (associated with thymoma or autoimmune disease), and Takotsubo (stress) cardiomyopathy. Giant cell myocarditis is a fulminant form with rapid progression to end-stage heart failure or cardiogenic shock; biopsy shows giant cells and inflammatory infiltrate. Peripartum cardiomyopathy occurs in the last trimester or first 5 months postpartum, disproportionately affecting multiparous, older, and African American women; mechanisms include oxidative stress from prolactin cleavage and angiogenic imbalance.

• Toxic/Drug-induced cardiomyopathy: Alcohol abuse is a major modifiable cause, particularly with consumption >90 g/week; ethanol and acetaldehyde cause direct myocyte toxicity, mitochondrial dysfunction, oxidative stress, and thiamine deficiency (contributing to wet beriberi in severe cases). Chemotherapy agents, particularly anthracyclines (doxorubicin, daunorubicin) and trastuzumab (HER2 inhibitor), cause dose-dependent and cumulative myocardial injury through topoisomerase inhibition, ROS generation, and iron-mediated oxidative stress; cumulative doxorubicin doses >450 mg/m² carry significant risk. Other cardiotoxic drugs include tyrosine kinase inhibitors (sunitinib, sorafenib), immune checkpoint inhibitors (anti-PD-1/PD-L1 agents), 5-fluorouracil, cocaine (via sympathomimetic effects and coronary vasospasm), and amphetamines. Radiation-induced cardiomyopathy develops years after thoracic radiation (e.g., breast cancer, Hodgkin lymphoma treatment) through direct myocyte injury and fibrosis. Recognition of these etiologies is critical because some are reversible with cessation (alcohol, some drug-induced cases).

• Ischemic cardiomyopathy: While technically distinct as ischemic cardiomyopathy (EF <40% due to CAD-related infarction), the distinction is important: dilated segments are localized to coronary territories with post-infarction remodeling, scar formation, and regional dysfunction. However, severe multivessel CAD with diffuse ischemia can cause global dysfunction mimicking DCM. Coronary angiography is essential to exclude CAD.

• Metabolic and infiltrative causes: Thyroid disease (hyperthyroidism causes high-output failure with eventual systolic dysfunction; hypothyroidism rarely causes primary systolic DCM but worsens existing disease), diabetes mellitus (cardiomyopathy independent of coronary disease, possibly via altered glucose metabolism and increased lipid accumulation), renal failure (uremic toxins, anemia, hypertension, secondary hyperparathyroidism), and nutritional deficiencies (thiamine in alcoholics causing wet beriberi, carnitine, selenium, and other trace elements) contribute to DCM. Hemochromatosis causes iron deposition and oxidative damage. Amyloidosis (AL or hereditary transthyretin) infiltrates myocardium, though typically with restrictive physiology initially.

• Hypertensive and tachycardia-related DCM: Severely uncontrolled hypertension with prolonged exposure can lead to systolic dysfunction beyond expected hypertrophic remodeling. Tachycardia-induced cardiomyopathy occurs with persistent tachyarrhythmias (supraventricular tachycardia, atrial flutter, or premature contractions with high burden); ventricular rate control often restores function.

• Other secondary causes: Peripartum cardiomyopathy (discussed above), pregnancy-related hypertension and preeclampsia, HIV/AIDS (direct viral myocarditis, opportunistic infections, or antiretroviral toxicity), Chagas disease (Trypanosoma cruzi causing chronic inflammation and fibrosis, endemic in Central/South America), connective tissue disorders (systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis), and endocrine disorders (pheochromocytoma, hyperthyroidism, acromegaly).

• Dyspnea: The most common presenting symptom, resulting from pulmonary edema due to elevated LV end-diastolic pressure and backward transmission to pulmonary veins. Dyspnea is initially exertional (as cardiac output cannot increase appropriately with activity) but progresses to orthopnea (requiring multiple pillows or sleeping in a chair due to redistribution of fluid from legs to lungs in supine position) and paroxysmal nocturnal dyspnea (abrupt awakening with severe dyspnea, often requiring standing to recover). Acute flash pulmonary edema with pink frothy sputum represents acute decompensation.

• Fatigue and reduced exercise tolerance: Results from inadequate cardiac output and inability to increase stroke volume with exertion; tissue oxygen delivery is impaired, and lactate accumulates. Patients report inability to perform previous activities and progressive symptom burden.

• Palpitations: Reflect supraventricular or ventricular arrhythmias, which are common due to enlarged chambers, electrical remodeling, and scarring. Atrial fibrillation develops in 20-50% of DCM patients and further reduces cardiac output by loss of atrial "kick" and rapid ventricular rates.

• Syncope or presyncope: Indicates either severe pump failure with inadequate cerebral perfusion, arrhythmia-related loss of consciousness, or both. Syncope in DCM portends poor prognosis and suggests increased sudden cardiac death risk.

• Orthopnea and dependent edema: Fluid retention from neurohormonal activation and poor renal perfusion leads to peripheral edema (typically bilateral, pitting, dependent—ankles and shins in ambulatory patients, sacral area in bedbound patients) and elevated jugular venous pressure (JVP). These findings reflect elevated systemic venous pressure from right ventricular dysfunction (either primary or secondary to elevated LV filling pressures).

• Nocturia and polyuria: Results from improved renal perfusion when supine at night and reduced sympathetic tone; worsening nocturia may indicate disease progression.

• Cardiomegaly: Displaced, diffuse, hyperdynamic apical impulse (point of maximal impulse) shifted laterally beyond the midclavicular line and inferiorly, indicating LV dilation. The impulse may be sustained (opposite of normal, brisk impulse). A prominent left parasternal lift (right ventricular heave) indicates RV dilation or hypertension.

• Auscultatory findings: S3 gallop (ventricular gallop) is a classic finding—a low-pitched, early diastolic sound from abrupt cessation of ventricular filling when the ventricle reaches its elastic limit; it reflects elevated filling pressures. A systolic murmur of secondary (functional) mitral regurgitation is common due to papillary muscle displacement and annular dilation; this is typically holosystolic and best heard at the apex, radiating to the axilla. Aortic regurgitation murmur (early diastolic, decrescendo) may occur if aortic root dilation is present. Distant heart sounds suggest pericardial effusion.

• Signs of pulmonary congestion: Crackles (rales) at lung bases from interstitial or alveolar edema; in acute flash pulmonary edema, crackles extend throughout the lung fields and pink-tinged frothy sputum may be present. Wheezing ("cardiac asthma") can occur.

• Signs of systemic venous congestion: Elevated JVP (>4 cm above the right atrium with patient at 45 degrees), hepatojugular reflux (increase in JVP with abdominal pressure, indicating hepatic congestion and elevated right atrial pressure), hepatomegaly (tender due to hepatic congestion), ascites (indicates advanced disease with elevated right atrial pressure >10 mmHg chronically), and peripheral edema.

• Indicators of poor perfusion: Cool extremities, narrow pulse pressure, weak pulse, reduced blood pressure (in advanced disease), and altered mental status or confusion (in severe cardiogenic shock).

Important clinical variants and presentations

• **Asymptomatic LV

Initial evaluation (every suspected case)

• ECG: nonspecific but rarely normal — sinus tachycardia, poor R-wave progression, LBBB or nonspecific intraventricular conduction delay, atrial fibrillation, low voltage, or frequent PVCs. A wide QRS matters because it determines later CRT candidacy.
• Chest radiograph: cardiomegaly with a cardiothoracic ratio >0.5, balanced four-chamber enlargement, cephalization of pulmonary vasculature, Kerley B lines, and effusions.
• Natriuretic peptides: BNP/NT-proBNP are elevated in proportion to wall stress; a low BNP (conventionally <100 pg/mL) makes untreated symptomatic heart failure unlikely. Obesity lowers, and renal failure and atrial fibrillation raise, these values.
• Laboratory screen for reversible causes: CBC, metabolic panel, TSH, iron studies with transferrin saturation and ferritin (hemochromatosis), HIV, and targeted testing for connective tissue disease, Chagas serology, or thiamine deficiency by exposure history.

Confirmatory imaging

• Transthoracic echocardiography is the definitive first-line diagnostic test: LVEF ≤40% with LV end-diastolic dimension ≥55 mm (men)/≥50 mm (women), global hypokinesis, spherical remodeling, functional mitral regurgitation from annular dilation and papillary muscle tethering, and possible apical thrombus.
• Cardiac MRI with late gadolinium enhancement adds tissue characterization: midwall septal striae favor nonischemic DCM, while subendocardial or transmural enhancement in a coronary territory indicates ischemic cardiomyopathy. LGE burden predicts arrhythmic risk.
• Coronary evaluation — CT angiography or invasive angiography — is required to exclude CAD sufficient to explain the dysfunction, since DCM is a diagnosis of exclusion.

Selective testing

• Endomyocardial biopsy is reserved for fulminant or rapidly progressive failure with hemodynamic compromise, high-grade block, or refractory ventricular arrhythmia, where giant cell, eosinophilic, or lymphocytic myocarditis would change therapy.
• Genetic testing and cascade screening: the ACC/AHA/HFSA 2022 heart failure guideline recommends genetic counseling/testing in idiopathic DCM and echocardiographic screening of first-degree relatives.

Immediate stabilization (acute decompensation)

• IV loop diuretic (furosemide) for the congested "wet" patient; supplemental oxygen and noninvasive positive-pressure ventilation for pulmonary edema. IV vasodilators (nitroglycerin) may be added when blood pressure permits.
• Cardiogenic shock (cold and wet, rising lactate, oliguria) is an emergency: inotropes such as dobutamine or milrinone plus temporary mechanical circulatory support, with early transfer to an advanced heart failure center.

Guideline-directed medical therapy for HFrEF — four pillars, per the 2022 AHA/ACC/HFSA guideline, each started at low dose and uptitrated

• ARNI (sacubitril/valsartan), preferred over ACE inhibitor or ARB; requires a 36-hour washout after an ACE inhibitor to avoid angioedema.
• Evidence-based beta blocker: carvedilol, metoprolol succinate, or bisoprolol — reverses catecholamine-mediated remodeling and β₁ downregulation. Start only when euvolemic.
• Mineralocorticoid receptor antagonist: spironolactone or eplerenone, blocking aldosterone-driven fibrosis.
• SGLT2 inhibitor: dapagliflozin or empagliflozin, with benefit independent of diabetes status.

Add-on and second-line

• Hydralazine plus isosorbide dinitrate: mortality benefit in self-identified Black patients on optimal therapy, and an alternative when renal function or hyperkalemia precludes RAAS blockade.
• Ivabradine for sinus rate ≥70 bpm despite maximally tolerated beta blockade; vericiguat in worsening HFrEF; digoxin reduces hospitalizations but not mortality.
• Loop diuretics relieve congestion only — no mortality benefit.
• Treat the cause: alcohol abstinence, thiamine repletion, rate control of tachycardia-mediated cardiomyopathy, iron chelation, immunosuppression for giant cell myocarditis.

Device and surgical therapy

• ICD for primary prevention when LVEF ≤35% and NYHA II–III persist after ≥3 months of optimized therapy, with meaningful expected survival.
• CRT when LVEF ≤35% with sinus rhythm and LBBB with QRS ≥150 ms.
• Durable LVAD and orthotopic heart transplantation for stage D disease.

Complications of the disease

• Progressive pump failure and cardiogenic shock: the dilated, spherical ventricle sits on the flat portion of the Frank-Starling curve, so preload reserve is exhausted. Signaled by hypotension, cool mottled extremities, narrow pulse pressure, rising lactate and creatinine, and altered mentation. Emergency.
• Sudden cardiac death: fibrosis and electrical remodeling create reentrant circuits; the arrest rhythm is typically ventricular fibrillation or pulseless VT (shockable) — immediate defibrillation. Emergency. Sustained monomorphic VT or syncope in DCM is a red flag.
• Atrial fibrillation: atrial stretch shortens refractoriness; loss of atrial kick plus rapid rates can precipitate acute decompensation and can itself be tachycardia-mediated cardiomyopathy.
• Intracavitary thrombus and systemic embolism: stasis in an akinetic, dilated LV (Virchow's triad) causes stroke, mesenteric or limb ischemia; suspect with a new focal deficit or apical thrombus on echo.
• Functional mitral regurgitation: annular dilation and papillary tethering produce a holosystolic apical murmur and worsen forward failure.
• Cardiorenal syndrome and congestive hepatopathy: venous congestion plus low output drive rising creatinine, diuretic resistance, transaminitis, and eventually cardiac cirrhosis.

Complications of therapy

• Hyperkalemia and acute kidney injury from combined RAAS blockade and MRA — check potassium and creatinine after each uptitration; peaked T waves demand emergency treatment.
• Symptomatic hypotension and angioedema with ARNI/ACE inhibitors; cough with ACE inhibitors; gynecomastia with spironolactone (switch to eplerenone).
• Euglycemic diabetic ketoacidosis and genital mycotic infection with SGLT2 inhibitors.
• Bradycardia or transient decompensation when beta blockers are started in a congested patient.
• Hypokalemia, hyponatremia, and gout from loop diuretics; hypokalemia potentiates digoxin toxicity (nausea, yellow-green visual halos, atrial tachycardia with block, scooped ST depression).
• ICD complications: inappropriate shocks, lead infection, and electrical storm (≥3 appropriate shocks in 24 hours) — an emergency requiring antiarrhythmics and sedation.

• The stem picture: dyspnea plus a laterally displaced, diffuse PMI, an S3 gallop, and a holosystolic apical murmur of functional mitral regurgitation, with balanced four-chamber enlargement on chest film. The single best next step is transthoracic echocardiography.
• Four pillars, not three: ARNI (or ACEI/ARB), evidence-based beta blocker, MRA, and SGLT2 inhibitor all reduce mortality in HFrEF per the 2022 AHA/ACC/HFSA guideline. Diuretics and digoxin relieve symptoms/hospitalizations only — picking a loop diuretic as the "mortality-reducing" answer is the classic trap.
• ICD timing: do not implant at diagnosis. Reassess LVEF after ≥3 months of optimized therapy; nonischemic DCM often improves enough to no longer meet the ≤35% threshold.
• Anticoagulate for a reason, not for the EF: warfarin/DOAC is indicated for atrial fibrillation, documented LV thrombus, or prior embolism — not for low ejection fraction alone.
• Etiology one-liners: titin (TTN) truncating variants are the most common monogenic cause; cumulative anthracycline dose drives doxorubicin cardiotoxicity (trastuzumab injury is typically dose-independent and often reversible); alcohol and tachycardia-mediated DCM can normalize with abstinence or rate control; Chagas disease in a Latin American immigrant with an apical aneurysm and right bundle branch block; Duchenne muscular dystrophy for X-linked DCM.
• Pregnancy: ACE inhibitors, ARBs, and ARNI are contraindicated — captopril's short half-life makes it useful for rapid titration outside pregnancy, never in it. Use hydralazine/nitrates plus a beta blocker in peripartum cardiomyopathy before delivery.
• Drugs to stop: verapamil and diltiazem (negative inotropes), NSAIDs, thiazolidinediones, and class IC antiarrhythmics.
• Common distractor: a murmur that softens with squatting and increases with Valsalva is HOCM, not DCM; DCM's functional MR murmur behaves like ordinary mitral regurgitation, increasing with increased afterload.